Potential significance of physiological and pharmacological glucocorticoids in early pregnancy.
BACKGROUND
Despite extensive studies of the developmental consequences of increased glucocorticoid exposure in mid- to late pregnancy, relatively little is known regarding the significance of glucocorticoids in early pregnancy. The objective of this review was to consider potential roles for this family of corticosteroids that might relate to early pregnancy.


METHODS
Although this is a narrative review, 249 source articles addressing potential effects of glucocorticoids on aspects of early pregnancy and development (published between 1997 and 2007) were identified using a systematic literature search. Additional articles (115) were identified if cited by the primary reference articles identified in the systematic phase of the review.


RESULTS
Much of the evidence to implicate glucocorticoids in early pregnancy comes from studies of steroid receptors and the 11beta-hydroxysteroid dehydrogenase enzymes, which modulate cortisol action in the endometrium/decidua, trophoblast, placenta and embryo/fetus. The evidence reviewed suggests that in early pregnancy the actions of glucocorticoids are balanced between positive effects that would promote pregnancy (e.g. stimulation of hCG secretion, suppression of uterine natural killer cells, and promotion of trophoblast growth/invasion) versus adverse effects that would be expected to compromise the pregnancy (e.g. inhibition of cytokine-prostaglandin signalling, restriction of trophoblast invasion following up-regulation of plasminogen activation inhibitor-1, induction of apoptosis, and inhibition of embryonic and placental growth).


CONCLUSIONS
Glucocorticoids exert many actions that could impact both negatively and positively on key aspects of early pregnancy. These steroids may also be implicated in obstetric complications, including intra-uterine growth restriction, pre-term labour, pre-eclampsia and chorio-aminionitis.
Centre for Developmental and Endocrine Signalling, Academic Section of Obstetrics and Gynaecology, Division of Clinical Developmental Sciences, St George's University of London, Cranmer Terrace, London SW17 0RE, UK. aemichae@sgul.ac.uk
Anthony E
AE
Michael
Aris T
AT
Papageorghiou
D042842:11-beta-Hydroxysteroid Dehydrogenases / Q000502:physiology; D000818:Animals; D006063:Chorionic Gonadotropin / Q000378:metabolism; D003656:Decidua / Q000378:metabolism; D010064:Embryo Implantation; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D005307:Fertilization in Vitro; D005938:Glucocorticoids / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007527:Isoenzymes / Q000502:physiology; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000033:anatomy & histology / Q000378:metabolism / Q000502:physiology; D011247:Pregnancy / Q000187:drug effects / Q000378:metabolism*; D011248:Pregnancy Complications / Q000139:chemically induced / Q000378:metabolism; D014327:Trophoblasts / Q000166:cytology / Q000378:metabolism
D006063:Chorionic Gonadotropin; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D007527:Isoenzymes; D042842:11-beta-Hydroxysteroid Dehydrogenases